Last reviewed · How we verify

A novel hGIIA-Vimentin Inhibitor

Filamon LTD · Phase 1 active Small molecule

Inhibits hGIIA-Vimentin interaction

Inhibits hGIIA-Vimentin interaction Used for Treatment of various cancers.

At a glance

Generic nameA novel hGIIA-Vimentin Inhibitor
SponsorFilamon LTD
Drug classVimentin inhibitor
TargethGIIA-Vimentin
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 1

Mechanism of action

This interaction is involved in various cellular processes, and its inhibition may have therapeutic effects.

Approved indications

Common side effects

No common side effects on file.